Valuation: Poxel

Market Cap 1.26Cr 1.41Cr 1.16Cr 1.05Cr 1.97Cr 133.65Cr 2Cr 14Cr 5.53Cr 70Cr 5.28Cr 5.17Cr 220.77Cr P/E 2023
-0.52x
P/E 2024 -0.36x
Enterprise Value 7.97Cr 8.92Cr 7.36Cr 6.67Cr 12Cr 846.76Cr 13Cr 89Cr 35Cr 443.65Cr 33Cr 33Cr 1.4TCr EV / Sales 2023
33.3x
EV / Sales 2024 11.2x
Free-Float
94.27%
Yield 2023 *
-
Yield 2024 -
1 day-6.97%
1 week+17.16%
Current month+2.00%
1 month-0.34%
3 months-13.73%
6 months-35.06%
Current year-25.90%
1 week 0.15
Extreme 0.1506
0.27
1 month 0.13
Extreme 0.1302
0.27
Current year 0.13
Extreme 0.1302
0.48
1 year 0.13
Extreme 0.1302
0.48
3 years 0.12
Extreme 0.115
0.95
5 years 0.12
Extreme 0.115
5.99
10 years 0.12
Extreme 0.115
13.8
Manager TitleAgeSince
Chief Executive Officer 59 10/06/2026
Director of Finance/CFO - 01/12/2022
Corporate Officer/Principal - 01/05/2023
Director TitleAgeSince
Director/Board Member - 31/07/2025
Director/Board Member - 31/07/2025
Director/Board Member 59 31/10/2025
Date Insider Type Main position Quantity % Market Cap. Importance
04/02/22 Exercice

Founder

67,000 0.2334%
04/02/22 Exercice

Founder

6,666 0.0232%
30/01/21 Free

Founder

25,263 0.0888%
Change 5-day change 1-year change 3-year change Capi.($)
-6.97%+17.16%-47.93%-50.67% 1.04Cr
+2.41%+0.29%+39.41%+72.14% 6.47TCr
-0.15%+7.50%+11.42%+71.27% 5.48TCr
+0.57%+4.60%+7.71%+90.93% 5.35TCr
+0.37%+4.67%+26.68%+49.64% 4.6TCr
-1.21%+2.32%+21.50%+118.33% 4.29TCr
-0.37%+5.07%+243.23%+789.58% 4.01TCr
+0.05%+0.21%+18.06%+48.50% 3.35TCr
+1.19%-4.98%+26.31%-0.76% 2.4TCr
-0.38%+5.68%+38.39%+28.35% 2.37TCr
Average -0.45%+3.89%+38.48%+121.73% 3.83TCr
Weighted average by Cap. +0.39%+2.73%+46.02%+142.83%

Financials

2023 2024
Net sales 19.81L 22.18L 18.3L 16.58L 31.03L 21Cr 31.54L 2.2Cr 87.19L 11Cr 83.25L 81.48L 35Cr 66.36L 74.31L 61.3L 55.56L 1.04Cr 71Cr 1.06Cr 7.38Cr 2.92Cr 37Cr 2.79Cr 2.73Cr 116.52Cr
Net income -3.51Cr -3.93Cr -3.24Cr -2.94Cr -5.5Cr -373.02Cr -5.59Cr -39Cr -15Cr -195.44Cr -15Cr -14Cr -616.16Cr -1.83Cr -2.05Cr -1.69Cr -1.53Cr -2.87Cr -194.59Cr -2.91Cr -20Cr -8.06Cr -101.95Cr -7.69Cr -7.53Cr -321.43Cr
Net Debt 4.64Cr 5.2Cr 4.29Cr 3.89Cr 7.27Cr 493.49Cr 7.39Cr 52Cr 20Cr 258.56Cr 20Cr 19Cr 815.16Cr 6.71Cr 7.51Cr 6.2Cr 5.62Cr 11Cr 713.11Cr 11Cr 75Cr 30Cr 373.62Cr 28Cr 28Cr 1.18TCr
Projected Income Statement - Annual - Poxel
Logo Poxel
Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders. For the treatment of NASH, PXL065 (deuterium-stabilized R-pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWYMEEG® (Imeglimin), Poxel's first-in-class product that targets mitochondrial dysfunction, is marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan.
Employees
5
Date Price Change Volume
23/26/23 €0.1734 -6.97% 5,44,304
22/26/22 €0.1864 -5.38% 4,19,071
21/26/21 €0.1970 +7.42% 17,27,432
20/26/20 €0.1834 -17.76% 38,48,782
19/26/19 €0.2230 +50.68% 76,67,004
  1. Stock Market
  2. Stocks
  3. POXEL Stock